Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: A case report

作者：Shad Aziza T^*; Huo Jeffrey S; Darcy Courtney; Abu Ghosh Amal; Esposito Giuseppe; Holuba Mary Jo; Robey Nancy; Cooke Kenneth R; Symons Heather J; Chen Allen R; Llosa Nicolas J

来源：Pediatric Blood and Cancer, 2017, 64(3): e26257.

DOI：10.1002/pbc.26257

• anti-PD1
• haploidentical bone marrow transplant
• Hodgkin lymphoma
• immunotherapy
• nivolumab
• relapse

To date, there has been a lack of pediatric experience regarding the efficacy and tolerability of immune checkpoint inhibitors after haploidentical hematopoietic stem cell transplant (HSCT). We present the case of a 22-year-old female with multiple-relapsed Hodgkin lymphoma (HL) who presented with a new relapse after haploidentical (post-haplo) HSCT. Anti-PD-1 therapy with nivolumab resulted in significant objective disease response and clinical improvement without notable side effects, including the absence of a graft-versus-host disease (GVHD). This case report suggests that immune checkpoint inhibition may be safely tolerated even in the setting of haploidentical HSCT, without triggering overt GVHD.

• 出版日期2017-3